Recent evidence suggested that inhibition of client kinases that catalyze the vast majority of Hsp90 PTMs can act synergistically with Hsp90 inhibitors, providing a novel therapeutic strategy to enhance the efficacy of Hsp90 inhibitors in cancer cells43,44. Here, HSP90AA1 is linked to cancer.